Document:

Exhibit 10.2

Exhibit 10.2

Confidential Materials omitted and filed separately with the

Securities and Exchange Commission. Asterisks denote omissions.

FIRST AMENDMENT OF LICENSE AGREEMENT

THIS FIRST AMENDMENT OF LICENSE AGREEMENT (the “First Amendment”) is made and entered into as
of the 20th day of May, 2010 (the “Effective Date”), by and between Idenix Pharmaceuticals, Inc., a
company organized under the laws of the State of Delaware with its principal place of business at
60 Hampshire Street, Cambridge, Massachusetts 02139, USA (“Idenix”), and ViiV Healthcare Company,
successor in interest to SmithKline Beecham Corporation, doing business as GlaxoSmithKline, a
company organized under the laws of the State of Delaware, with its principal place of business at
Five Moore Drive, Research Triangle Park, North Carolina, 27709, USA (“ViiV”).

W I T N E S S E T H:

WHEREAS, Idenix and SmithKline Beecham Corporation, doing business as GlaxoSmithKline have
previously entered into and executed a License Agreement dated February 4, 2009 (the “Agreement”);

WHEREAS, SmithKline Beecham Corporation assigned the Agreement to ViiV on October 29, 2009 and

WHEREAS, the Parties desire to amend the Agreement as hereafter provided, in accordance with
Section 14.12 of the Agreement.

NOW, THEREFORE, in consideration of the premises, the mutual covenants contained herein and
other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
parties hereby agree as follows:

	1.	 	Capitalized terms used herein but not defined herein will have the meanings ascribed to such
terms in the Agreement.
	 
	2.	 	Section 5.2(a) entitled “Development Milestones” will be amended by:

	 	(a)	 	deleting the Milestone Payment for the milestone described in subparagraph
(iii) of in the Milestone Payment chart (Successful Completion of a segment II
reproductive toxicity study) and replacing it as follows:
	 
	 	 	 	“[**] U.S. Dollars (US $[**]); and
	 
	 	(b)	 	deleting the Milestone Payment for the milestone described in subparagraph
(vii) of in the Milestone Payment chart (First patient dosed in first Phase II Clinical
Trial studying chronic dosing (24 – 48 weeks) in combination with other ARTs in HIV-infected
patients as defined in the Development Plan) and replacing it as follows:
	 
	 	 	 	“[**] U.S. Dollars (US $[**]).

 

 

 

For the avoidance of doubt, the Milestone Payment chart in Section 5.2(a) will be restated in
its entirety to include the replacement language:

	 	 	 
	Milestone Event:	 	Milestone Payment:
	(i) Successful Completion of development
of the first formulation of a Licensed
Compound

	 	[**] U.S. Dollars (US $[**])
	(ii) Successful Completion of development
of the first fixed dose combination
formulation of a Licensed Compound

	 	[**] U.S. Dollars (US $[**])
	(iii) Successful Completion of a segment
II reproductive toxicity study

	 	[**] U.S. Dollars (US $[**])
	(iv) Successful Completion of a six (6)
month rodent chronic toxicology study

	 	[**] U.S. Dollars (US $[**])
	(v) Successful Completion of a chronic
toxicology non-rodent study of at least nine
(9) months

	 	[**] U.S. Dollars (US $[**])
	(vi) Successful Completion of a
carcinogenicity program in at least one (1)
rodent species

	 	[**] U.S. Dollars (US $[**])
	(vii) First patient dosed in first Phase II
Clinical Trial studying chronic dosing (24 –
48 weeks) in combination with other ARTs in
HIV-infected patients as defined in the
Development Plan

	 	[**] U.S. Dollars (US $[**])
	(viii) First patient dosed in Phase III
Clinical Trial of a Product for HIV

	 	[**] U.S. Dollars (US $[**])
	(ix) Acceptance for review by the FDA of an
NDA for first Product for HIV

	 	[**] U.S. Dollars (US $[**])
	(x) Acceptance for review by EMEA of an NDA
for first Product for HIV

	 	[**] U.S. Dollars (US $[**])
	(xi) Acceptance for review by MHLW of an NDA
for first Product for HIV

	 	[**] U.S. Dollars (US $[**])
	(xii) Receipt of Regulatory Approval from
the FDA for first Product for HIV

	 	[**] U.S. Dollars (US $[**])
	(xiii) First Commercial Sale of the first
Product for HIV in the first of one (1) of
the following countries: [**].

	 	[**] U.S. Dollars (US $[**])
	(xiv) Receipt of Regulatory Approval from
the MHLW for first Product for HIV

	 	[**] U.S. Dollars (US $[**])

 

 

 

	4.	 	Except as specifically provided herein, the terms and provisions of the Agreement will remain
in full force and effect.
	 
	5.	 	This First Amendment may be executed in one or more counterparts, each of which will be
deemed an original, and all of which will constitute one and the same instrument.

IN WITNESS WHEREOF, the parties hereto have caused this First Amendment to be executed by their
duly authorized representatives as of the Effective Date of this First Amendment.

	 	 	 	 	 	 	 	 	 	 	 
	Idenix Pharmaceuticals, Inc.	 	 	 	ViiV Healthcare Company	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Jean Pierre Sommadossi
	 	 	 	By:
	 	/s/ John Pottage	 	 
	 

	 	 

Name: Jean Pierre Sommadossi, Ph.D.
	 	 	 	 	 	 

Name: John Pottage
	 	 
	 

	 	Title: Chief Executive Officer
	 	 	 	 	 	Title: Chief Scientific and Medical OfficerExhibit 10.3

Exhibit 10.3

FOURTH AMENDMENT OF LEASE

THIS FOURTH AMENDMENT OF LEASE (this “Amendment”) is made as of this
29th day of
June, 2010,
by and between RB KENDALL FEE, LLC (“Landlord”) and IDENIX PHARMACEUTICALS, INC., having a mailing
address at One Kendall Square, Building 1400, Cambridge, Massachusetts 02139 (“Tenant”).

R E C I T A L S:

A. Reference is made to an Indenture of Lease dated June 8, 2005 by and between One Kendall
Square Associates, LLC, the predecessor in title to Landlord, and Tenant, as amended by a First
Amendment of Lease dated July 24, 2006, Second Amendment of Lease dated September 7, 2006, and a
Third Amendment of Lease dated July 23, 2009, demising approximately 36,513 s.f. of rentable square
feet of space on a portion of the first, fourth, fifth and penthouse floors of Building No. 1400,
One Kendall Square, Cambridge, Massachusetts (the “Lease”). Capitalized terms used but not defined
herein shall have the same meaning as in the Lease.

B. Landlord and Tenant are the current holders, respectively, of the lessor’s and
lessee’s interests in the Lease.

C. Landlord and Tenant now desire to amend the Lease as set forth herein.

D. Capitalized terms not defined herein shall have the meanings set forth in the Lease.

A G R E E M E N T S:

NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, and
for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, Landlord and Tenant hereby agree to amend the Lease as follows:

1. Surrendered Space; Effective Date. On or before the Effective Date (defined
below),
Tenant shall quit, vacate and deliver up, in accordance with the surrender provisions of the Lease,
including Section 22, and free of all subtenants, that portion of the Premises demised under the
Lease shown cross-hatched on Exhibit A attached hereto, consisting of (a) approximately
4,692 rentable square feet of space on the 1st floor of the Building; and (b)
approximately 9,325 rentable square feet of space on the 4th floor of the Building (the
“Surrendered Space”). After Tenant surrenders the portion of the Surrendered Space located
on the 4th floor, any demising of such space to separate it from the adjacent space on
the 4th floor shall be completed by Landlord at Landlord’s cost. Upon the Effective Date, (x) the
Premises demised pursuant to the Lease shall consist of approximately 22,496 rentable square feet;
(y) the Surrendered Space shall be deemed to no longer constitute a portion of the Premises demised
pursuant to the Lease; and (z) Tenant shall have no leasehold or other right, title, or interest in
or to the Surrendered Space. Tenant shall remain liable for any and all obligations and agreements
under the Lease relating to the Surrendered Space accruing on or before the Effective Date and for
any amounts incurred by Landlord or due and payable under the Lease in the event Tenant fails to
quit and deliver up the Surrendered Space on or before the Effective Date. As used herein, the
“Effective Date” shall mean the later to occur of (a) April 1, 2011, or (b) the date Tenant
quits, vacates and delivers up the Surrendered Space in accordance with the terms and conditions of
this Agreement. In the event that Tenant does not vacate the Surrendered Space on or April 1, 2011,
Tenant shall be considered a tenant-at-sufferance as described in Section 22 of the Lease with
respect to the Surrendered Space and shall pay rent for the Surrendered Space to Landlord as
provided therein for each day after April 1, 2011, that Tenant occupies the Surrendered Space, in
whole or in part.

 

 

 

2. Condition of Premises. Tenant acknowledges and agrees that it currently occupies
the Premises and is familiar with the condition thereof and that the Premises as affected hereby is
leased to Tenant in “As-Is” condition without any representation or warranty, express or implied,
as to the condition or fitness for Tenant’s use thereof.

3. Term. The Lease term is hereby extended for an additional period (the “Extended
Term”), commencing on April 1, 2011, and expiring at 11:59 p.m. on December 31, 2013 (the
“Termination Date”), unless otherwise terminated in accordance with the Lease.

4. Basic Annual Rent. Beginning on the Effective Date, the Yearly Rent in respect of
the Premises as affected hereby shall be as follows:

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Rentable Square	 	 	 	 	 	 	 	 	 	 	Rent Per Square	 
	Period	 	Feet	 	 	Yearly Rent	 	 	Monthly Rent	 	 	Foot	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Effective Date — Termination Date
	 	 	22,496	 	 	$	714,248.00	 	 	$	59,520.67	 	 	$	31.75	 

Additional Rent; Tenant’s Proportionate Share. As of the Effective Date, Tenant’s
Proportionate Building Share shall be reduced to 17.41% and Tenant’s Proportionate Common Area
Share shall be reduced to 3.52%.

5. Parking. Upon the Effective Date, the number of parking passes available for
Tenant’s use in the OKS Garage pursuant to, and in accordance with, Section 29.18 of the Lease,
shall be reduced to twenty-two (22). The parties acknowledge and agree that the monthly charge for
such passes shall be based upon market rates then charged in the OKS Garage and in similar garages
located in the East Cambridge/Kendall Square market, as such rates may vary from time to time (as
of the date of this Amendment the market rate is $220.00 per month).

6. Brokers. Landlord and Tenant each warrant and represent to the other that they have
dealt with no brokers in connection with the negotiation or consummation of this Amendment other
than Beal and Company, Inc. and Richards, Barry, Joyce & Partners (collectively, the “Broker”) and
in the event of any brokerage claim against either party by any person claiming to have dealt with
either Landlord or Tenant in connection with this Amendment, other than the Broker, the party with
whom such person claims to have dealt shall defend and indemnify the other party against such
claim. Landlord shall pay any commission due the Broker pursuant to a separate agreement.

7. Ratification. In all other respects the Lease shall remain unmodified and shall
continue in full force and effect, as amended hereby. The parties hereby ratify, confirm, and
reaffirm all of the terms and conditions of the Lease, as amended hereby.

 

2

 

IN WITNESS WHEREOF the parties hereto have executed this Amendment of Lease on the date First
written above in multiple copies, each to be considered an original hereof, as a sealed instrument.

	 	 	 	 	 	 	 	 	 	 	 
	LANDLORD:	 	 	 	TENANT:	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	RB KENDALL FEE, LLC	 	 	 	IDENIX PHARMACEUTICALS, INC.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Robert L. Beal
	 	 	 	By: 	/s/ Jean Pierre Sommadossi	 	 
	 

	 	 
	 	 	 	 	 
	 	 
	 

	 	Name: Robert L. Beal
	 	 	 	 	Name: Jean Pierre Sommadossi, Ph.D.
	 	 
	 
	 	Title: Its Authorized Signatory	 	 	 	 	Title:   	Chairman and CEO	 	 
	 

	 	 	 	 	 	 	 	Hereunto duly authorized	 	 

 

3

 

Exhibit A

Surrendered Space

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}]]